College of Health Sciences

Department of Internal Medicine

Title: The magnitude and associated factors of dysnatremia and dyskalemia in the ICUs of BLH, St peter's and Yekatit 12 hospitals.

By: Atikelt Zerihun, MD, Internal Medicine Resident

Advisors:

Addisu Melkie, MD, Assistant Professor of Internal Medicine and Nephrology

A thesis to be submitted to the Department of Internal Medicine, College of Health Sciences,

Addis Ababa University, in partial fulfillment of the specialty certificate in Internal Medicine.

December 2021

Addis Ababa, Ethiopia

Acknowledgment

First of all, I would like to express my sincere gratitude to my advisors for giving me this opportunity to conduct this research and for his assistance and continuous guidance. I am also grateful to my family and friends for all their unconditional support and encouragement. Above all, I would like to thank God who helped me all through this.

Acronyms

Abbreviation	Definition
ACEI	Angiotensin converting enzyme inhibitors
AKI	Acute kidney injury
BLH	Black lion hospital
CNS	Central nervous system
CRRT	Continues renal replacement therapy
DM	Diabetes mellites
HF	Heart failure
IAH	Intensive care unit acquired hypernatremia
ICU	Intensive care unit
IU/l	International unit per liter
Meq/l	Milliequivalent per liter
NOACs	Novel oral anticoagulants
NSAID	Non-steroidal anti-inflammatory drug
qSOFA	Quick sequential organ failure assessment score

Abstract

Title: The magnitude, associated factors and outcome of dysnatremia and dyskalemia in the ICUs of BLH, St peter's and Yekatit 12 hospitals.

Background: Electrolyte disturbance is common in critically ill patients and it is independently associated with increased short-term and long-term morbidity and mortality.

Objectives: The main objective of this study was to assess the prevalence, associated factors and outcome of dysnatrmia and dyskalemia in the ICUs of BLH, St peter's and Yekatit 12 hospitals.

Methods: This was a prospective, hospital-based cohort study of critically ill patients admitted to the ICUs of BLH, St peter's and Yekatit12 hospital between May 1, 2021 and August 31, 2021. A structured questionnaire was used to collect information on sociodemographic characteristics, clinical profile at admission, and outcomes at discharge. Trained physician data clerks collected the data from the chart, interview and electronic medical records. Data was entered into EpiInfo 3.1 and was exported to SPSS version 25 for analysis. To identify determinants of dysnatremia and dyskalemia, bivariable and multivariable binary logistic regression analyses were done. Statistical significance was considered at the level of significance of 5%, and adjusted odds ratio (AOR) with 95% confidence interval (CI) was used to present the estimates of the strength of the association.

Result: A total of 157 patients included in the study. The majority (64.2%) of study participants are from St. Peter. More than one-third (38.4%) of them were in the age group of 31-50 years. The frequency of hyponatremia was 49.68% while Hypernatremia has been found in 25.48% of ICU admitted patients. The magnitude of hypo and hyperkalemia is found out to be 39.49% and 24.2% respectively. A total of 70.06% of patients were dysnatremic while 61.15% were dyskalemic.The odds of hyponatremia increase 4.53 times with admission diagnosis of endocrine than non-endocrine admissions [AOR=4.53; 95% CI: 1.64 - 12.53], Similarly the odds of hyponatremia increased 3.95 times with those taking beta blockers [AOR= 3.95; 95% CI: 1.43 - 10.97].hypernatremia increased 3.17 times in those who took sedatives as compared to those who didn’t [AOR=3.17; 95% CI: 1.28- 7.86] and in those with diagnosis of AKI in their hospital stay.a single unit increase on the mean chloride increased the odds of hypernatremia by1.16 times [AOR=1.16; 95% CI: 1.08- 1.24].Those with admission diagnosis of COVID 19 were 75%

less risk of developing hypokalemia than those with non-covid admissions [AOR=0.25; 95% CI: 0.11- 0.61].Those with use of beta blockers were 95% less risk of developing hyperkalemia as compared to those who don't use betablockers [AOR=0.05; 95% CI: 0.01-0.48]. one unit increase in the mean urea increases the risk of hyperkalemia by 1.02 times [AOR=1.02; 95% CI: 1.01- 1.03]. Hypernatremia increased the risk of death 2.73 times among patients in the ICU than those with no hypernatremia. [AOR=2.73; 95% CI: 1.28- 5.85]. similarly, those patients in the ICU with hyperkalemia were 2.43 times more at risk to die than those with no hyperkalemia. [AOR=2.43; 95% CI: 1.13- 5.25].

Conclusion: This study demonstrated that dysnatrmia and dyskalemia are frequent findings in the critically ill. There are different determinant factors for the development of dysnatremia and dyskalemia in the ICU. Critically ill patients with hypernatremia and hyperkalemia had a higher incidence of thirty-day ICU mortality.

KEY- WORD: Dysnatremia, Dyskalemia, thirty-day ICU mortality

Contents

1. Introduction

1.1 Background

Electrolytes are minerals and compounds which are electrically charged that help our body do much of its work. They are involved in many essential processes in our body such as metabolic and homeostatic functions which including enzymatic and biochemical reactions , maintenance of cell membrane structure and function ,neurotransmission , nerve signal conduction ,cardiovascular function ,muscle contraction , bone composition and fluid and acid regulation.[1]

Electrolyte disturbances are common in critically ill patients. critical patients in ICU are more susceptible to electrolyte abnormalities than the non-critically ill patients. The estimated incidence of electrolyte disturbance in an ICU patient is 25%.[2] There are multiple factors may be involved in electrolyte abnormalities in critically ill patients in ICU , including altered absorption and distribution , inadequate or excess administration , alteration in excretion through gl or renal loss , hormonal alteration as well as changes in fluid status and shifts. other factors include administration of drugs such as diuretics, sodium bicarbonate , glucose solution , sympathomimetics, insulin and dobutamine[1, 3]

Dysnatremia is a common a clinical problem in patients admitted to the intensive care unit. Most cases of dysnatremia are acquired after the patient is admitted to the ICU. A study conducted recently involving over 151,000 adult patients from 77 ICUs over a period of 10 years has shown that many cases of dysnatremia are acquired in the ICU, and that the severity of dysnatremia is associated with poor outcome in a graded fashion. Another study on the ICU patients with dysnatremias corroborated these findings, reporting that ICU-acquired hyponatremia and ICU-acquired hypernatremia were associated with increased mortality.[4]

Hyponatremia is a common electrolyte disturbance occurring in critically ill patients. It is also the most common electrolyte abnormality in hospitalized patient. it is defined as a serum sodium concentration less than 135 mmol/L. Mild hyponatremia is defined as serum sodium between 130-134.moderate hyponatremia is when plasma sodium is between 125 and 130 while severe or profound hyponatremia is when plasma sodium level is less than 125. low plasma sodium represents a relative fluid excess together with impaired ability of the kidney to excrete water free electrolyte. Hyponatremia can be classified based on the volume status, osmolality and urinary sodium in to into hypertonic, isotonic and hypotonic types. Hypotonic hyponatremia can

be further classified as hypervolemic, euvolemic and hypovolemic. A few studies have revealed that ICU-acquired hyponatremia is not uncommon and has been observed to affect critically ill patients at a rate of 1 in 9 or higher and it is associated with increased mortality.[5–7]

Clinical manifestations related to hyponatremia are predominantly the expression of CNS dysfunction. This includes headache, nausea, emesis, abdominal cramp, mild neurologic impairment, gait impairment, restlessness, lethargic, confusion, seizure and coma. The pattern of symptoms correlates with the level of hyponatremia and whether the disorder has developed rapidly or not.[8]

hypernatremia is a water metabolism disorder and usually defined as a plasma sodium concentration above 140meq/L. The main mechanism is a net loss of body water relative to sodium and can occur with or without a loss or even gain in body sodium content. in non-critical general- medical-surgical patients the prevalence of hypernatremia has been estimated at up to 1%. There is a higher prevalence in critically ill patients which is 10-26%. Hypernatremia can be present at ICU admission, but it develops during the ICU stay in about three-quarters of cases. The main causes of hypernatremia in critically ill patents are: renal water loss, inability to express thirst and inadequate fluid management by ICU physicians.[9, 10]

Hypernatremia can be life threatening and the clinical consequence include but not limited to cardiac dysfunction, neurologic consequences, and insulin resistance in addition to impaired gluconeogenesis. Slowly developing hypernatremia is better tolerated as brain can adapt to hyperosmolality by solute gain and prevent significant volume loss.[11] Several studies suggest an association between hypernatremia and hospital mortality .The overall mortality is in adult patient with hypernatremia is approximately 40-70%, although the mortality rate directly attributed to hypernatremia itself is likely lower. However, most of the studies were retrospective single-center studies in small numbers of patients or focused exclusively on hypernatremia at ICU admission[1][9]

Potassium disorders are common in intensive care unit. Hypokalemia is defined as serum potassium level less than 3.5 mEq per L and considered severe if below 2.5 meq/L or if a patient is symptomatic. It occurs in up to 21% of hospitalized patients and 2% to 3% of outpatients. The main mechanisms by which hypokalemia develop in ICU are intracellular shifts of potassium,

increased losses of potassium, or, less commonly, decreased ingestion or administration of potassium. Metabolic alkalosis, drugs like □□adrenergic agonists (e.g., albuterol), insulin, theophylline, and caffeine cause hypokalemia by intracellular shift of potassium. Common causes of hypokalemia due to potassium losses include potassium-wasting diuretics (loop and thiazide), sodium polystyrene sulfonate, corticosteroids (especially mineralocorticoids such as fludrocortisone), aminoglycosides, amphotericin B, magnesium depletion, renal replacement therapies (e.g., hemodialysis, continuous renal replacement therapy [CRRT]), and GI losses (e.g., diarrhea, nasogastric suctioning)[1, 12]

Hypokalemia is often asymptomatic, especially when it is mild (serum potassium between 2.5 and 3.5meq/L). but severe hypokalemia(serum potassium less than 2.5 meq/L) is associated with profound signs.[13] The sign and symptoms are primarily neuromuscular, including paralysis, weakness, nausea, vomiting, constipation, respiratory muscle weakness, and rhabdomyolysis. the most feared complication are cardiac arrhythmias, especially in patients with hypertension, myocardial infarction/ischemia or heart failure.[4]

Hyperkalemia is a potentially life-threatening electrolyte abnormality. Although there is no single agreed upon definition for hyperkalemia, most literatures define hyperkalemia as a plasma level > 5.5 mmol/L and severe hyperkalemia as > 6.5 mmol/L.[14] since acute renal failure is common in ICU, hyperkalemia is common in these settings. Other causes of hyperkalemia include drugs like ACEI, NSAIDs, succinylcholine, □-adrenergic blockers and digoxin overdose. hypoaldosteronism and metabolic acidosis are other causes. Signs and symptoms of hyperkalemia include muscle twitching, cramping, weakness, ascending paralysis, ECG changes (e.g., tall peaked T-waves, prolonged PR-interval, widened QRS complex, shortened QT-interval) and arrhythmias (e.g., bradyarrhythmias, ventricular fibrillation, asystole)[1, 14, 15]

1.2 Statement of the problem

Surprisingly, there are very few data on dysnatremia and dyskalemia in hospitalized patients from the developing world, and from Africa and Ethiopia in particular. I found three Ethiopian studies published about electrolyte disorders. The first one is on hyponatremia in patients hospitalized for heart failure. This was a descriptive, prospective, hospital-based cohort study of patients with HF admitted to Jimma University Hospital, Ethiopia, between November 1, 2013 and July 31, 2014.In this study 152 participants admitted with HF, 44 (28.9%) had hyponatremia, which is defined as serum sodium level <135 mmol/L. Patients on salt restriction, on chronic diuretic treatment (furosemide and spironolactone), and with impaired renal function at admission were found to be highly affected. Hyponatremia was found to be associated with increased in-hospital mortality and longer hospital stay. Patients with hyponatremia also had lower blood pressure and poor functional status at discharge. [16]The second one is published in 2019 which is done at Tikur Anbessa Specialized Hospital about assessment of electrolyte balance in patients with cardiovascular disease. In this study 36.2% had serum Na+ imbalance (25.8% hyponatremia and 10.4% hypernatremia) and 22.7% had serum K+ imbalance(13.5% hypokalemia and 9.2% hyperkalemia)[17]The other one was on serum electrolytes disorder and its associated factors among adults admitted with metabolic syndrome in Jimma 2020 . The overall prevalence of electrolyte disorders was 44.1% with hyponatremia 42.9% as the leading electrolyte disorder followed by hypokalemia 20.7% .[18]

These three researches were done about electrolytes on specific disease entity which are not inclusive for all patients and were not done in ICU setting.

Hence, this study aimed to assess the local magnitude of dysnatremia and dyskalemia among ICU patients with associated outcome.

2. Literature review

Fluid and electrolyte balance is vital in maintaining homeostasis in the body, it has important role in protecting cellular function, tissue perfusion and acid-base balance. Electrolyte imbalances are common findings in many diseases. Fluid and electrolyte balance must also be maintained for the management of many clinical conditions. electrolyte disturbance is very prevalent in expired ICU patients which is compatible with the findings of some other studies. Even though mortality of ICU patients is linked, in greater part, to organ dysfunction, the severity of serum sodium and potassium disturbances remains a significant predictor of mortality. Thus, early identifying and correcting electrolyte disturbances in ICU patients is important.[19, 20]

As we go through works of literature, there are various studies done on magnitude of individual electrolyte abnormalities and the determinant factors. In one observational, prospective study of a series of ICU patients during a 12-month period, the frequency of hyponatremia on ICU admission was 34.3% of all ICU admissions and euvolemic hyponatremia was the most common (50.6%) type of hyponatremia. In this study, SIADH is the most common cause of hyponatremia.[5]

Whether dysnatremias play a role as independent factors to predict mortality in surgical critically ill patients was studied in Brazil. it was a 2-year retrospective study which included 1599 patients. in this study both hyponatremia and hypernatremia had an influence on mortality in the ICU. (Relative risk [RR]=1.91 [95% CI=1.13–3.17]) and (RR=5.45 [95% CI=3.65–8.1]) respectively. This association was greater in patients with hypernatremia mortality in the ICU. When the independent variables that could be associated with mortality are evaluated using multivariate analysis and outcome of patients and its correlation with dysnatremia , It was observed that the need for vasopressors, blood transfusions, dialysis-requiring acute kidney injury (AKI), mechanical ventilation, and cases of severe sepsis and septic shock were independent factors associated with mortality.[21]

Another retrospective cohort study based on the prospective registry of all critically ill patients admitted to the medical ICU from south Korea conducted from January 1, 2015 to December 31,

2018. They found out that 16.2% of critically ill medical patients who had normal sodium concentration at the time of ICU admission developed new-onset hyponatremia within the first 48 h after admission. in this study hematologic malignancy and initial potassium were independently associated with the development of ICU-acquired hyponatremia. In addition, net volume balance was the only management profile significantly associated with ICU-acquired hyponatremia[6]

OUTCOMEREA is a retrospective observational study on a prospectively collected multicenter database done in France to assess the epidemiological characteristics and prognostic impact of ICU acquired hypernatremia. In this study 11.1% experienced mild and 4.2% moderate to severe ICU acquired hypernatremia yielding an overall frequency of 15.3%. The time from ICU admission to ICU acquired hypernatremia was 5 days (3–8) for mild cases and 6 days (3–10) for moderate to severe cases. Independent factors associated with male gender; greater disease severity at ICU admission; and septic shock, acute respiratory failure or coma at ICU admission. Before adjustment, hospital mortality was 15.2% in patients without IAH, 29.5% in patients with mild and 46.2% in patients with moderate to severe ICU acquired hypernatremia.[10]

A retrospective study from Netherland, in two large cohort of ICU patients, found a shift in the incidence of dysnatremias. The incidence of hyponatremia decreased over the study period, whereas the incidence of hypernatremia is increased. The shift was explained by the increased use of diuretics and hydrocortisone.[22] In another observational study of postoperative patients , In the subgroup of patients who presented to the ICU with normal sodium values ,13% developed dysnatremia during the ICU stay. The data also show significantly higher rates of congestive heart failure and liver failure in all dysnatremic patient groups, a higher incidence of diabetes and renal failure in patients with hyponatremia, and a higher incidence of hypertension among patients with hypernatremia. In this observational study of postoperative patients, dysnatremia is common and is associated with increased risk of mortality in postoperative patients requiring intensive care. They found that fluctuations in serum sodium were associated with an increase in 28-day mortality, even in those patients with normal serum sodium measurements during the course of the ICU stay.[23]

A two-year retrospective study from Turkey analyzing the ICU records of 440 patients, Hypokalemia was found in 40% of patients. Hypokalemia was observed for the first time on 2.3 +/-1.3th days of patients' ICU stay. Hypothermia, polyuria, vomiting and diarrhea found to be related with increased incidence of hypokalemia. Additionally, the application of dialysis, administration of insulin, diuretics and beta-adrenergic agents was found significantly correlated with higher incidence of hypokalemia. Blood transfusion was also found to be highly correlated with hypokalemia.[13] A cross-sectional study was carried out at cardiac surgical intensive care unit in Rawalpindi, Pakistan, from July – Nov 2013. Hypokalemia (K<3.5 mmo*l*/*l*) developed in 33% patients and hyperkalemia (K>5 mmo*l*/*l*) developed in 18% patients. in this study 33% of Hyperkalemic patients had from renal impairment while 50% had hypertension[7]

A prospective cohort study from Thailand involving critically ill patients admitted to the medical ICU from May 2012 to February 2013 showed abnormal mean serum potassium levels were associated with significantly higher ICU mortality (24.3% vs. 39.5%, p=0.04).

patients with abnormal potassium levels had longer ICU and hospital lengths of stay than patients with normal potassium levels; however, the difference in these parameters between the two groups was not statistically significant. even though the incidence of overall arrhythmia was not significantly different between patients with normal and abnormal potassium levels , a significantly higher incidence of malignant arrhythmia (i.e., ventricular tachycardia and ventricular fibrillation) was found among patients with abnormal potassium levels (p=0.02)[24]

3. Significance of the study

As discussed in the introduction and literature review, electrolyte disturbances are common in critically ill patients. There are many factors which are associated in the development of ICU acquired dysnatremia and dyskalemia which can be identified early and corrected. After knowing the magnitude of dysnatremia and dyskalemia and associated risk factors in this study it helps physicians to understand how common these electrolyte imbalances are and to frequently monitor them.

It will help the patients to have accurate, timely diagnosis of these electrolyte imbalances and early management which can possibly impact mortality.

As there is no data for our setup this will be a good starting point to have an idea on magnitude of dysnatremia and dyskalemia and associated factors in ICU. It will also give future researchers to do more on risk factors and management protocol.

4. Objectives

4.1 General objective

- The general objective of this study is to assess the magnitude and associated factors of dysnatremia and dyskalemia in the ICUs of BLH, St peter's and Yekatit 12 hospitals.

4.2 Specific Objectives

- To determine the prevalence of dysnatremia and dyskalemia in ICU.
- To determine the factors associated with dysnatremia and dyskalemia in ICU.
- To assess the influence of dysnatremia and dyskalemia on patient's outcomes in ICU.

5. Methods and Materials

5.1 Study Area and target population

The study was conducted among critically ill patients admitted to the ICUs of Black lion specialized hospital, St peter's and Yekatit 12 hospitals.

5.2 Eligibility criteria

5.21 Inclusion criteria

- Age ≥ 18 yrs.
- ICU stay for 24hrs or more.
- At least 2 determinations of electrolyte during ICU stay and the interval between the 1st and the last one should be at least 24hrs.

- For patients who experienced multiple sodium or potassium disturbance events, each event was analyzed separately

- Events and outcomes developed within 1 month after ICU admission were analyzed. This allowed having more electrolyte determinations

5.22 Exclusion criteria

- Patients who have been previously admitted and analyzed.

-.

-.

5.3 Sample size determination

- Sample size for the patients will be calculated with the following formula: assuming 95% CI

$$n = \frac{Z^2 x\ (p)(1-p)}{d^2} = \frac{1.96^2 x 0.104(1-0.104)}{0.05^2} = 144$$

Z α/2 = is standard normal variant (at 5% type 1 Error (P <0.05) it is 1.96

d = margin of error was taken as 0.05.

q =1-p: the probability of non-occurrence of the event of interest.

p = expected proportion of the population with the event outcome.

The calculated sample size is 144 and a 10% loss was added with resulting total size of 159 patients.

5.4 Study Period

The data collection was conducted from May 1, 2021, to August31, 2021.

5.5 Study Design

A prospective cohort study was conducted in critically ill patients admitted in the ICUs of the mentioned hospitals.

5.6 Variables

5.61 Outcome variables

- Magnitude of dysnatremia in ICU
- Magnitude of dyskalemia in ICU
- Factors associated with ICU acquired dysnatremia and dyskalemia.
- Clinical outcome at the end of 30 days

5.62Explanatory variable

- Underlying condition
- Baseline electrolyte at admission
- Use of diuretics
- Diagnosis of AKI during stay
- Diagnosis of diabetes
- Vasoactive agent use
- Transfusion of blood products
- Serum creatinine and BUN
- qSOFA score

5.7 Data collection method

Standardized case report format (CRF) prepared to collect enrolled patient's data. Baseline characteristics at the time of admission, including age, sex, marital status, place of residency were recorded. Admission diagnosis was recorded for all patient and Serum electrolytes and organ function tests were followed during the stay. Medications known to affect sodium and potassium concentration and intravenous fluids were recorded. Use of blood products agents, the presence of diabetes and the diagnosis of AKI during hospital stay were assessed. Thirty-day outcome was assessed for all patients admitted to the ICU in the time period.

5.8 Data quality assurance

The quality of the data was censured by a mechanism such as random onsite visits during the filling of the data by the supervisor. The data collectors were trained in the survey tool to let them understand well how to use it.

5.9 Data management and analysis plan

Data was checked for completeness, edited, coded and entered Epi data version 3.1 and exported to SPSS version 24.0 statistical software for cleaning and analysis. Frequencies and proportion are used to describe study subjects and socio-demographic characteristics. Continuous variables are expressed as means ± standard deviation. Differences between group means were tested using two-tailed Student's t-test. Proportions is reported as percentages and compared between groups with Chi-square. Tables are used to present results. A p value of less 0.05 is considered statistically significant.

5.10 Operational definitions

- ✓ Intensive care unit (ICU) may be defined as a service for patients who have potentially recoverable conditions, who can benefit from more detailed observation and invasive treatment than can be provided safely in an ordinary ward or high dependency area. It is usually reserved for patients with threatened or established organ failure, often arising as a result or complication of an acute illness or trauma, or as a predictable phase in a planned treatment program. Intensive care represents the highest level of continuing patient care and treatment.
- ✓ Hyponatremia- sodium level of less than 135 mEq/L
    - ➢ Mild = 130-134 mEq/L
    - ➢ Moderate= 125-129 mEq/L
    - ➢ Severe= <125 mEq/L
- ✓ Hypernatremia- sodium level of greater than 145 mEq/L
    - ➢ Mild= 146-149 mEq/L
    - ➢ Moderate = 150-169 mEq/L
    - ➢ Severe= >170 mEq/L
- ✓ Sodium disorders (dysnatremia)- either hypo/hyperkalemia

- ✓ Hypokalemia-potassium level of less than 3.5 mEq/L

- Mild = 3-3.4 mEq/L
- moderate= 2.5-2.9 mEq/L
- Severe= < 2.5 mEq/L

✓ Hyperkalemia - potassium level of greater than 5.5 mEq/L

- Mild= 5.5-6.5 mEq/L
- Moderate= 6.5-7.5 mEq/L
- Severe=>7.5mEq/L

✓ Potassium disorders (dyskalemia)- either of hypo/hyperkalemia

5.11 Ethical Clearance

Informed written consent was collected from participants of the study or their next of kin if the patient is unable to give informed consent. Ethical clearance was obtained from the AAU CHS Institutional Review Board. The safety and privacy of subjects was protected by using their identification numbers in data collection and analysis process.

5.12 Dissemination of result

The finding of this study will be submitted to Addis Ababa University, College of health sciences. It will also be submitted to Ministry of Health of Federal Democratic Republic of Ethiopia. It will be presented at different national and international seminars and workshops. Finally, it will be published on peer reviewed journals.

6. Results

6.1. Socio-demographic characteristics

The majority (64.2%) of study participants are from St. Peter and more than one-third (38.4%) of them were in the age group of 31-50 years. Most (74.8%) of them were urban residents at the time of data collection. More specifically most of them were residents of Addis Ababa. Socio-demographic characteristics of the study participants are shown in table 1.

Table 1. Socio-demographic characteristics

Variables		Frequency (%)	Value percent
Hospital (n=159)			
	St. Peter	102 (64.2)	64.2
	Black lion	41 (25.8)	25.8
	Yekatit 12	16 (10.1)	10.1
Age in year (n=154)			
	18-30	37 (23.3)	23.3
	31-50	61 (38.4)	38.4
	51-90	56 (35.2)	35.2
Sex (n=159)			
	Male	102 (64.2)	64.2
	Female	57 (35.8)	35.8
Residence (n=149)			
	urban	119 (74.8)	74.8
	rural	18 (11.3)	11.3
	semi urban	12 (7.5)	7.5
Region (n=148)			
	Addis Ababa	113 (71.1)	71.1
	Oromia	29 (18.2)	18.2
	Amhara	2 (1.3)	1.3
	SNNPR	4 (2.5)	2.5

6.2 Admission diagnosis

The study participants were admitted by different diagnosis. About 65% and 41% of participants were admitted for respiratory and CVS problem, respectively. About one-third (32.1%) of participants were admitted in neurology and 43.4% were admitted in COVID-19. Only 3.8% and 6.3% were admitted for hematology and infection, respectively. Admission diagnosis are shown in table 2.

Table 2. Admission diagnosis

Variables (n=159)	Frequency	Percent
Respiratory		
Yes	103	64.8
No	56	35.2
CVS		
Yes	65	40.9
No	94	59.1
GIT		
Yes	21	13.2
No	138	86.8
Hematology		
Yes	6	3.8
No	153	96.2
Renal		
Yes	25	15.7
No	134	84.3
Neurology		
Yes	51	32.1
No	108	67.9
Endocrine		
Yes	30	18.9
No	129	81.1
COVID19		
Yes	69	43.4
No	90	56.6
Surgical		
Yes	26	16.4
No	133	83.6
Infectious		
Yes	10	6.3
No	149	93.7

6.3 Medications

Diuretics were administered for 47.2% of the study participants. High percentage (34.6%) of diuretics was accounted by furosemide. Vasoactive medications were administered for 25.8% of participants. Antibiotics and corticosteroids were administered for 89.3% and 69.2% of the study participants, respectively. Regarding antiplatelet & anticoagulants, heparin was administered for 70.4% of the study participants. Among fluids 70,1% of patients were given Normal saline while 28.2 and 7.7% of patients took Ringer's lactate and D5W respectively. Medications administered to the study participants on their hospital stay are shown on table 3.

Table 3. Medications and fluids

Medications

Variables (n=159)	**Frequency**	**Percent**
Diuretics		
Furosemide		
Yes	55	34.6
No	104	65.4
Thiazide		
Yes	10	6.3
No	149	93.7
Spironolactone		
Yes	10	6.3
No	149	93.7
Vasoactive		
Epinephrine		
No	134	84.3
Yes	25	15.7
Norepinephrine		
Yes	9	5.7
No	150	94.3
Dopamine		
Yes	7	4.4
No	152	95.6
Medications		
Beta-blocker		
Yes	27	17
No	132	83
ACEI		

Yes	14	8.8
No	145	91.2
Antibiotics		
Yes	142	89.3
No	17	10.7
Corticosteroids		
Yes	110	69.2
No	49	30.8
Sedatives		
Yes	56	35.2
No	103	64.8
Proton pump inhibitors		
Yes	136	85.5
No	23	14.5
Antiplatelet and anticoagulants		
Aspirin		
Yes	12	7.5
No	147	92.5
Heparin		
Yes	112	70.4
No	47	29.6
Warfarin		
Yes	7	4.4
No	152	95.6
NOACs		
Yes	10	6.3
No	149	93.7

IV fluids

Variables	**Frequency**	**Percent**	**Value percent**
Normal saline			
Yes	110	69.2	70.1
No	47	29.6	29.9
D5W			
Yes	12	7.5	7.7
No	144	90.6	92.3
Ringer's lactate			
Yes	44	27.7	28.2
No	112	70.4	71.8

6.4 Clinical parameters

Almost 32% of the study participants were diagnosed with AKI during their hospital stay. Renal replacement therapy was done for 3.8% of the study participants. Blood product was transfused to 11.3%. Of the total study participants, 14.5% were diabetic. Clinical parameters of the participant in their ICU stay are shown in table 4.

Table 4. Clinical parameters

Variables	**Frequency**	**Percent**
Diagnosis of AKI during stay		
Yes	51	32.1
No	108	67.9
Renal replacement therapy		
Yes	6	3.8
No	153	96.2
Blood product transfusion		
Yes	18	11.3
No	141	88.7
Is the patient diabetic		
Yes	23	14.5
No	136	85.5

6.5. Prevalence of dysnatremia and dyskalemia

Figure 1. the prevalence of dysnatremia and dyskalemia



Figure 2. Hyponatremia based on severity



Figure 3. hypernatremia based on severity



Figure 4. hypokalemia based on severity



Figure 5. hyperkalemia based on severity



6.6. Factors affecting hyponatremia

In this study based on p value of bivariable analysis and the potential to confound the association factors with hyponatremia 7 variables were identified as candidate variables for multivariable analysis. These are admission diagnosis of neurology, admission diagnosis of surgery, admission diagnosis of endocrine, mean chloride, use of Beta-blocker, use of corticosteroids, patient being diabetic. the result however identified, admission diagnosis of endocrine, mean chloride, use of Beta-blocker as independent variables affecting hyponatremia.

The odds of hyponatremia increase 4.53 times with admission diagnosis of endocrine than non-endocrine admissions [AOR=4.53; 95% CI: 1.64 - 12.53], Similarly the odds of hyponatremia increased 3.95 times with those taking beta blockers than those who don't take beta blockers. [AOR= 3.95; 95% CI: 1.43 - 10.97]. Whereas when there is 1 unit increase in the mean chloride the odds of hyponatremia decrease by 4% [AOR=0.96; 95% CI: 0.91- 0.99]. Patients with hyponatremia are less likely to be given D5W.

Table 5. Bivariable and Multivariable Logistic Regression analysis results of factors associated with hyponatremia

Explanatory variables		**Hyponatremia**		**COR 95%CI**	**AOR 95% CI**
		Yes	No		
Admission diagnosis of Neurology	Yes	20 (39.2)	31 (60.8)	0.52(0.27,1.04)	0.77(0.34,1.74)
	No	59 (55.1)	48 (44.9)	1	1
Admission diagnosis of Endocrine	Yes	22 (75.9)	7 (24.1)	3.97(1.58,9.95) *	4.53(1.64,12.53)*
	No	57 (44.2)	72 (55.8)	1	1
Admission diagnosis of Surgical	Yes	8 (30.8)	18 (69.2)	0.38(0.16,0.94) *	1.1(0.36,3.32)
	No	71 (53.8)	61 (46.2)	1	1
Mean chloride		85.29±44.2	74.6±48.47	0.94(0.89,0.98) *	0.96(0.91,0.99)*
Beta blocker	Yes	20 (74.1)	7 (25.9)	3.49(1.38,8.81) *	3.95(1.43,10.97) *
	No	59 (45)	72 (55)	1	1
Corticosteroids	Yes	61 (56)	48 (44)	2.05(1.02,4.12) *	1.63(0.72,3.68)
	No	18 (38.3)	29 (61.7)	1	1
Is the patient diabetic	Yes	15 (68.2)	7 (31.8)	2.41(0.93,6.29)	0.34(0.04,3.37)
	No	64 (47.1)	72 (52.9)	1	1
D5W	Yes	3 (25)	9 (75)	0.3(0.08,1.16)	0.86(0.03.1.2)
	No	75 (52.4)	68 (47.6)	1	1

6.7. Factors affecting hypernatremia

Based on p value of bivariable analysis and the potential to confound the association factors with hypernatremia 6 variables were identified as candidate variables for multivariable analysis these are, admission diagnosis of surgery, mean chloride, use of norepinephrine, use of sedatives, Diagnosis of AKI during stay, blood product transfusion the result however identified, mean chloride, use of sedatives, diagnosis of AKI during stays as independent variables affecting hypernatremia.

The odds of hypernatremia increased 3.17 times in those who took sedatives as compared to those who didn't [AOR=3.17; 95% CI: 1.28- 7.86]. likewise, those with diagnosis of AKI during their hospital stay increased the odds of hypernatremia by 3.13 times than those with no diagnosis of AKI during their hospital stay [AOR=3.13; 95% CI: 1.25- 7.85]. And a single unit increase on the mean chloride increased the odds of hypernatremia by1.16 times [AOR=1.16; 95% CI: 1.08- 1.24]. NS administration is also associated with hypernatremia and patients are more likely to take D5W if they are hypernatremia.

Table 6. Bivariable and Multivariable Logistic Regression analysis results of factors associated with hypernatremia

Explanatory variables		**Hypernatremia**		**COR 95%CI**	**AOR 95% CI**
		Yes	No		
Admission diagnosis of Surgical	Yes	12 (46.2)	14 (53.8)	3.18(1.33,7.65) *	0.86(0.23,3.2)
	No	28 (21.2)	104 (78.8)	1	1
Mean chloride		110.44±11.44	99.35±10.59	1.18(1.09,1.26) *	1.16(1.08,1.24) *
Norepinephrine	Yes	5 (55.6)	4 (44.4)	4.19(1.07,16.48) *	1.39(0.25,7.63)
	No	34 (23)	114 (77)	1	1
Sedatives	Yes	23 (41.1)	33 (58.9)	3.4(1.62,7.17) *	3.17(1.28,7.86) *
	No	17 (17)	83 (83)	1	1
Diagnosis of AKI during stay	Yes	21 (41.2)	30 (58.8)	3.24(1.54,6.84) *	3.13(1.25,7.85) *
	No	19 (17.8)	88 (82.2)	1	1
Blood product transfusion	Yes	9 (50)	9 (50)	3.52(1.29,9.62) *	1.75(0.41,7.43)
	No	31 (22.1)	109 (77.9)	1	1

Normal saline	Yes	33 (30.3)	76 (69.7)	2.48(1.01,6.11) *	2.01(0.53,6.21)
	No	7 (14.9)	40 (85.1)	1	1
D5W	Yes	8 (66.7)	4 (33.3)	7.23(2.04,25.58) *	3.25(1.98,4.21)
	No	31 (21.7)	112 (78.3)	1	1
Ringer's lactate	Yes	15 (34.1)	29 (65.9)	1.86(0.87,4.05)	1.32(2.1,3.2)
	No	24 (21.6)	87 (78.4)	1	1

6.8. Factors affecting hypokalemia

Based on p value of bivariable analysis and the potential to confound the association factors with hypokalemia 11 variables were identified as candidate variables for multivariable analysis these are, age, rural residency, admission diagnosis of respiratory, Mean chloride, admission diagnosis of GIT, use of sedatives, admission diagnosis of Neurology, admission diagnosis of COVID 19, use of spironolactone, use of corticosteroids, use of heparin and being diabetic patient, the result however identified admission diagnosis of covid 19 as independent variables affecting hypokalemia.

Those with admission diagnosis of COVID 19 were 75% less risk of developing hypokalemia than those with non-covid admissions [AOR=0.25; 95% CI: 0.11- 0.61].

Table 7. Bivariable and Multivariable Logistic Regression analysis results of factors associated with hypokalemia

Explanatory variables		**Hypokalemia**		**COR 95%CI**	**AOR 95% CI**
		Yes	No		
Age		43.34±17.47	49.28±18.45	0.98(0.96,1)	0.99(0.97,1.02)
Living area	Urban	44 (37.3)	74 (62.7)	1	1
	Rural	11 (61.1)	7 (38.9)	2.64(0.95,7.32)	1.09(0.32,3.72)
	Semi urban	3 (25)	9 (75)	0.56(0.14,2.18)	0.25(0.05,1.14)
Respiratory	Yes	31 (30.4)	71 (69.6)	0.35(0.18,0.69) *	2.17(0.65,7.29)
	No	31 (55.4)	25 (44.6)	1	1
GIT	Yes	12 (57.1)	9 (42.9)	2.32(0.91,5.89)	0.74 (0.21,2.57)

	No	50 (36.5)	87 (63.5)	1	1
Neurology	Yes	31 (60.8)	20 (39.2)	3.8(1.89,7.65) *	2.25(0.92,5.49)
	No	31 (29)	76 (71)	1	1
Covid 19	Yes	13 (19.1)	55 (80.9)	0.19(0.09,0.41) *	0.25(0.11,0.61) *
	No	49 (54.4)	41 (45.6)	1	1
Mean chloride		105.45±11.3	100.14±11.73	1.06(1.01,1.1) *	1.04(0.99,1.09)
Spironolactone	Yes	7 (70)	3 (30)	3.95(0.98,15.88)	5.3(0.85,33.18)
	No	55 (37.2)	93 (62.8)	1	1
Corticosteroids	Yes	32 (29.4)	77 (70.6)	0.24(0.11,0.49) *	0.47(0.16,1.36)
	No	30 (63.8)	17 (36.2)	1	1
Heparin	Yes	38 (34.2)	73 (65.8)	0.46(0.23,0.92) *	0.75(0.24,2.3)
	No	24 (53.3)	21 (46.7)	1	1
Is the patient diabetic	Yes	3 (13.6)	19 (86.4)	0.21(0.06,0.73) *	0.51(0.12,2.21)
	No	59 (43.4)	77 (56.6)		1
Normal saline	Yes	51 (46.8)	58 (53.2)	2.88(1.33,6.23) *	2.11(0.21,2.32)
	No	11 (23.4)	36 (76.6)	1	1
Ringer's lactate	Yes	26 (59.1)	18 (40.9)	3.01(1.46,6.19) *	4.12(0.32,2.23)
	No	36 (32.4)	75 (67.6)	1	1

* Statistically significant at P-value ≤0.05

6.9. Factor associated with hyperkalemia

Based on p value of bivariable analysis and the potential to confound the association factors with hyperkalemia 13 variables were identified as candidate variables for multivariable analysis these are, age, admission diagnosis of respiratory, Mean urea, admission diagnosis of Neurology, admission diagnosis of COVID 19 ,admission diagnosis of surgery, admission diagnosis of endocrine, use of furosemide, use of Epinephrine, use of Betablockers, use of corticosteroids, use of heparin, Diagnosis of AKI during hospital stay the result however identified 6 variables which are admission diagnosis of respiratory, admission diagnosis of neurology, mean urea, use of epinephrine, use of betablockers, and use of corticosteroids as independent variables affecting hyperkalemia.

Those with admission diagnosis of respiratory were 81% less risk to develop hyperkalemia as compared to those with non-respiratory case admission. [AOR=0.19; 95% CI: 0.04- 0.96]. Similarly, those who were admitted with admission diagnosis of neurology were 94% less risk of developing hyperkalemia [AOR=0.06; 95% CI: 0.01- 0.39]. Whereas, one unit increase in the mean urea increases the risk of hyperkalemia by 1.02 times [AOR=1.02; 95% CI: 1.01- 1.03]. Similarly, epinephrine usage increased the odds of hyperkalemia by 3.9 times than non-usage [AOR=3.9; 95% CI: 1.17- 13.04].

Those with use of beta blockers were 95% less risk of developing hyperkalemia as compared to those who don't use betablockers [AOR=0.05; 95% CI: 0.01- 0.48]. However, those who use corticosteroids were 11.98 times more risk to develop hyperkalemia than those who don't use corticosteroids. [AOR=11.98; 95% CI: 1.52- 94.79].

Table 8 Bivariable and Multivariable Logistic Regression analysis results of factors associated with hyperkalemia

Explanatory variables		**Hyperkalemia**		**COR 95%CI**	**AOR 95% CI**
		Yes	No		
Age		52.54±19.37	45.12±17.58	1.02(1.01,1.04) *	1.01(0.98,1.04)
Respiratory	Yes	29 (28.4)	73 (71.6)	2.08(0.9,4.78)	0.19(0.04,0.96) *
	No	9 (16.1)	47 (83.9)	1	1
Neurology	Yes	4 (7.8)	47 (92.2)	0.18(0.06,0.55) *	0.06(0.01,0.39) *
	No	34 (31.8)	73 (68.2)	1	1
Endocrine	Yes	11 (37.9)	18 (62.1)	2.31(0.98,5.47)	2.26(0.77,6.59)
	No	27 (20.9)	102 (79.1)	1	1
Covid	Yes	25 (36.8)	43 (63.2)	3.44(1.59,7.42) *	1.95(0.43,8.84)
	No	13 (14.4)	77 (85.6)	1	1
Surgical	Yes	2 (7.7)	24 (92.3)	0.22(0.05,0.99) *	0.37(0.05,2.56)
	No	36 (27.3)	96 (72.7)	1	1
Mean Urea		82.31±69.74	53.98±45.37	1.01(1.002,1.016) *	1.02(1.01,1.03) *
Frusemide	Yes	21 (38.2)	34 (61.8)	3.13(1.47,6.63) *	0.71(0.24,2.1)
	No	17 (16.5)	86 (83.5)	1	1
Epinephrine	Yes	11 (44)	14 (56)	3.06(1.25,7.48) *	3.9(1.17,13.04) *
	No	27 (20.5)	105 (79.5)	1	1
Beta blocker	Yes	3 (11.1)	24 (88.9)	0.34(0.09,1.21)	0.05(0.01,0.48) *
	No	35 (26.7)	96 (73.3)	1	1
Corticosteroids	Yes	33 (30.3)	76 (69.7)	3.65(1.32,10.05) *	11.98(1.52,94.79) *
	No	5 (10.6)	42 (89.4)	1	1
Heparin	Yes	32 (28.8)	79 (71.2)	3.24(1.17,8.95) *	4.17(0.82,21.27)
	No	5 (11.1)	40 (88.9)	1	1
Diagnosis of AKI during stay	Yes	19 (37.3)	32 (62.7)	2.75(1.29,5.84) *	1.46(0.39,5.44)
	No	19 (17.8)	88 (82.2)	1	1

* Statistically significant at P-value ≤0.05

6.10. Factors predicting patient's thirty days outcome in the ICU

Two variables Hyperkalemia and Hypernatremia were found to be independent determinants of patient's outcome in the ICU.

Hypernatremia increased the risk of death 2.73 times among patients in the ICU than those with no hypernatremia. [AOR=2.73; 95% CI: 1.28- 5.85]. similarly, those patients in the ICU with hyperkalemia were 2.43 times more at risk to die than those with no hyperkalemia. [AOR=2.43; 95% CI: 1.13- 5.25].

Table 9. Factors predicting 30 days outcomes in the ICU

		Outcome		**COR 95%CI**	**AOR 95% CI**
		Discharged	Dead		
Hypernatremia	Yes	14(35)	26(65)	2.67(1.27,5.63) *	2.73(1.28,5.85) *
	No	69(59)	48(41)	1	1
Hyponatremia	Yes	41(52.6)	37(47.4)	1.02(0.55,1.92)	1.5(0.74,3.04)
	No	42(53.2)	37(46.8)	1	1
Hyperkalemia	Yes	14(36.8)	24(63.2)	2.37(1.11,5.02)*	2.43(1.13,5.25) *
	No	69(58)	50(42)	1	1
Hypokalemia	Yes	34(54.8)	28(45.2)	0.88(0.46,1.67)	1.29(0.11,15.28)
	No	49(51.6)	46(48.4)	1	1
Dysnatremia	Yes	53(63.9)	57(36.1)	1.89(0.94,3.83)	0.68(0.09,4.69)
	No	30(63.8)	17(36.2)	1	1
Dyskalemia	Yes	47(49)	49(51)	1.5(0.79,2.9)	0.91(0.43,1.96)
	No	36(59)	25(41)	1	1

* Statistically significant at P-value ≤0.05

6.11. Thirty-day Outcomes based on admission diagnosis

More than half of the patients with admission diagnosis of respiratory have an outcome of death 54(52.9%). Similarly, more death was recorded among those admitted with a diagnosis of endocrine 17(56.7%). Whereas, nearly two third of patients with admission diagnosis of neurology had an outcome of discharge from ICU.

Admission diagnosis		**Outcome**	
		Discharged	Died
Admission diagnosis of Respiratory		48(47.1)	54(52.9)
Admission diagnosis of CVS		33(51.6)	31(48.4)
Admission diagnosis of GIT		9(45.0)	11(55)
Admission diagnosis of Hematology		2(33.3)	4(66.7)
Admission diagnosis of Renal		12(48)	13(52)
Admission diagnosis of Neurology		33(64.7)	18(35.3)
Admission diagnosis of Endocrine		13(43.3)	17(56.7)
Admission diagnosis of Rheumatology		0	0
Admission diagnosis of COVID 19		35(51.5)	33(48.5)
Admission diagnosis of Surgical		15(57.7)	11(42.3)
Admission diagnosis of Infectious		5(50)	5(50)

Table 10. 30 days outcomes based on admission diagnosis

7. Discussion

This study tried to assess the magnitude, associated factors and thirty days outcome of dysnatremia and dyskalemia in patients admitted to the intensive care units of BLH, St peter's and Yekatit 12 hospital. The majority (64.2%) of study participants are from St. Peter while patients from BLH and Yekatit 12 account for 28.8% and 10.1% respectively. There is a slight male predominant gender distribution with a male to female ratio of 1.8:1. More than one-third (38.4%) of them were in the age group of 31-50 years. Most (74.8%) of them were urban residents at the time of data collection. More specifically most of them were residents of Addis Ababa.

The study participants were admitted by different diagnosis. About 65% and 41% of participants were admitted for respiratory and CVS problem, respectively. About one-third (32.1%) of participants were admitted in neurology and 43.4% were admitted in COVID-19. Only 3.8% and 6.3% were admitted for hematology and infection, respectively.

Among medications, diuretics were administered for 47.2% of the study participants. High percentage (34.6%) of diuretics was accounted by furosemide. Vasoactive medications were administered for 25.8% of participants. Regarding antiplatelet & anticoagulants, heparin was administered for 70.4% of the study participants. Normal saline was administered for 70.1% of patients while ringer's lactate and D5W was given to 28.2% and 7.7% of patients.

Almost 32% of the study participants were diagnosed with AKI during their hospital stay. Renal replacement therapy was done for 3.8% of the study participants. Blood product was transfused to 11.3%. Of the total study participants, 14.5% were diabetic.

The findings of the study reveal that the frequency of hyponatremia was 49.68% while the Hypernatremia has been found in 25.48% of ICU admitted patients. The magnitude of hypo and hyperkalemia is found out to be 39.49% and 24.2% respectively. A total of 70.06% of patients were dysnatremic while 61.15% were dyskalemic. This study showed a higher prevalence of dysnatremia and dyskalemia compared to other studies, one possible reason is that most studies

assess electrolyte imbalances which occurred after admission to the ICU and dyskalemia or dysnatremia prior to admission is an exclusion criterion for most studies.

In this study there was a significant association between having an endocrine diagnosis at admission and hyponatremia. Similarly, the odds of hyponatremia increased 3.95 times with those taking beta blockers than those who don't take beta blockers. Whereas when there is 1 unit increase in the mean chloride the odds of hyponatremia decrease by 4%. This is in contrast to South Korean study which showed hematologic malignancy and net volume balance which showed independent association with hyponatremia.

Overall, the odds of hypernatremia increased 3.17 times in those who took sedatives as compared to those who didn't. likewise, those with diagnosis of AKI during their hospital stay increased the odds of hypernatremia by 3.13 times than those with no diagnosis of AKI during their hospital stay. One possible reason for this association can be the development of hypernatremia in patients recovering from AKI. There was also an association between the administration of normal saline and development of hypernatremia which is consistent with other studies. There was an association between hypernatremia and the administration of D5W.This finding is probably the result of treatment with D5W in patient who are already hypernatremia single unit increase on the mean chloride increased the odds of hypernatremia by1.16 times.

A two-year retrospective study from Turkey analyzing the ICU records of 440 patients, Hypokalemia was found in 40% of patients. The application of dialysis, administration of insulin, diuretics and beta-adrenergic agents was found significantly correlated with higher incidence of hypokalemia. Blood transfusion was also found to be highly correlated with hypokalemia. In our study, those with admission diagnosis of COVID 19 were 75% less risk of developing hypokalemia than those with non-covid admissions.

In this study Those with use of beta blockers were 95% less risk of developing hyperkalemia as compared to those who don't use betablockers. However, those who use corticosteroids were 11.98 times more risk to develop hyperkalemia than those who don't use corticosteroids. Those patients admitted with diagnosis of respiratory and neurologic conditions had 81% and 94% lower risk of developing hyperkalemia.

The study showed Hyperkalemia and Hypernatremia to be independent determinants of patient's thirty days outcome in the ICU. Hypernatremia increased the risk of death 2.73 times among patients in the ICU than those with no hypernatremia. Similarly, those patients in the ICU with hyperkalemia were 2.43 times more at risk to die than those with no hyperkalemia. These findings are consistent with several studies which suggested increase in ICU mortality with hypernatremia and hyperkalemia. In contrast to several other studies, this study didn't show significant association between hyponatremia and hypokalemia and mortality in the ICU.

8. Limitation of the study

The major limitation of this study is the small sample size which made it difficult to do a more reliable subgroup analysis. This was because of the low number of admissions and turnover in the ICUs. Another limitation is the difference in the ICU setups among the respective hospitals and the blood samples were processed in different laboratory setting which might have impact on the results.

Some of the patient who received some of the medications and IV fluids after they already developed the electrolyte abnormalities or as a treatment for the specific electrolyte disturbance so it might be difficult to establish a clear correlation and it might create a chicken egg dilemma. This was observed in the case of hypernatremia in which patients took D5W as a treatment for hypernatremia.

The other limitation of the study is that study only assessed the thirty-day mortality.

9. Conclusion and recommendation

Dysnatremia and dyskalemia are frequent findings in critically ill patient. Endocrine diagnosis and use of beta blockers are strongly associated with hyponatremia. When there is 1 unit increase in the mean chloride the odds of hyponatremia decrease by 4%. The odds of hypernatremia increase in those taking sedatives and those who developed AKI during their ICU stay. An increase in mean chloride level is also associated with hypernatremia. Those with admission diagnosis of COVID 19 had a less risk of developing hypokalemia. An increase in the mean urea level is associated with increases the risk of hyperkalemia. Beta blocker use is also associated

with lesser risk of hyperkalemia. Hyperkalemia and Hypernatremia were found to be independent determinants of patient's outcome in the ICU.

As it has already been mentioned, the study has a small sample size so we recommend future researches include a large number of patients. It is also recommended to assess the magnitude of ICU acquired dysnatremia and dyskalemia in patients who don't have these electrolyte imbalances at admission. It is also recommended to assess the magnitude of other electrolyte imbalances like magnesium and calcium.

10. References

[1] Kraft MD, Btaiche IF, Sacks GS, et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. *Am J Heal Pharm* 2005; 62: 1663–1682.

[2] Samaritan BG. Electrolyte disturbances associated with medications in the critically ill. *Int J Intenive Care* 2012; 19: 83–88.

[3] In NM, In P, Sadeghi-bojd S, et al. Electrolyte Disturbances in PICU : A Cross Sectional Study. Epub ahead of print 2019. DOI: 10.5812/numonthly.87925.Research.

[4] Lee JW. Fluid and electrolyte disturbances in critically ill patients. *Electrolyte and Blood Pressure* 2010; 8: 72–81.

[5] Padhi R, Panda B, Jagati S, et al. Hyponatremia in critically ill patients. *Indian J Crit Care Med* 2014; 18: 83–87.

[6] Sim JK, Ko RE, Na SJ, et al. Intensive care unit-acquired hyponatremia in critically ill medical patients. *J Transl Med* 2020; 18: 1–9.

[7] Zahid M, Khan A, Abbas S, et al. Frequency of dyskalemia and dysnatremia in surgical intensive care unit. *Dysnatremia Dyskalemia Pak Armed Forces Med J* 2014; 1: 39–43.

[8] Rafat C, Flamant M, Gaudry S, et al. Hyponatremia in the intensive care unit : How to avoid a Zugzwang situation ? *Ann Intensive Care*. Epub ahead of print 2015. DOI: 10.1186/s13613-015-0066-8.

[9] Arora SK. Hypernatremic Disorders in the Intensive Care Unit. 2013; 28: 37–45.

[10] F F, Darmon M, Timsit J, et al. Association between hypernatraemia acquired in the ICU and mortality : a cohort study. 2010; 2510–2515.

[11] Alansari M, Abdulmomen A, Hussein M, et al. Acquired hypernatremia in a general surgical Intensive Care Unit: Incidence and prognosis. *Saudi J Anaesth* 2016; 10: 409–413.

[12] Viera AJ, Wouk N. Potassium Disorders: Hypokalemia and Hyperkalemia.

[13] Gerçek A, Umuroğlu T, Inci F, et al. The etiology and incidence of hypokalemia in intensive care unit. *Marmara Med J* 2003; 16: 32–35.

[14] Care I, Dépret F, Peacock WF, et al. Management of hyperkalemia in the acutely ill

patient. *Ann Intensive Care*. Epub ahead of print 2019. DOI: 10.1186/s13613-019-0509-8.

[15] Brueske B, Sidhu MS, Schulman-Marcus J, et al. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. *J Am Heart Assoc*; 8. Epub ahead of print 2019. DOI: 10.1161/JAHA.118.011814.

[16] Ali K, Workicho A, Kebede Gudina E. Hyponatremia in patients hospitalized with heart failure: a condition often overlooked in low-income settings. *Int J Gen Med* 2016; 2016: 9–267.

[17] Yuan J, Zou XR, Han SP, et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE). *BMC Nephrol*. Epub ahead of print 2017. DOI: 10.1186/s12882-017-0441-9.

[18] Diribsa GC, Kinfe Y, Abdissa SG. Assessment of Renal Function and Electrolyte Balance in Patients with Cardiovascular Disease at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. *Sci J Med Res* 2019; 03: 70–78.

[19] Mousavi SJ. Comparison of the Serum Electrolyte Levels among Patients Died and Survived in the Intensive Care Unit Comparison of the Serum Electrolyte Levels among Patients Died and Survived in the Intensive Care Unit.

[20] Kadri A. General characteristics of patients with electrolyte imbalance admitted to emergency department. *World J Emerg Med* 2013; 4: 113.

[21] Nicolini EA, Nunes RS, Santos G V., et al. Could dysnatremias play a role as independent factors to predict mortality in surgical critically ill patients? *Med (United States)* 2017; 96: 5–9.

[22] Oude Lansink-Hartgring A, Hessels L, Weigel J, et al. Long-term changes in dysnatremia incidence in the ICU: a shift from hyponatremia to hypernatremia. *Ann Intensive Care* 2016; 6: 1–8.

[23] Marshall DC, Salciccioli JD, Goodson RJ, et al. The association between sodium fluctuations and mortality in surgical patients requiring intensive care. *J Crit Care* 2017; 40: 63–68.

[24] Tongyoo S, Viarasilpa T, Permpikul C. Serum potassium levels and outcomes in critically ill patients in the medical intensive care unit. *J Int Med Res* 2018; 46: 1254–1262.

11. APPENDIX

Annex I:

1. English Version Questionnaire

Data extraction check list to assess magnitude of dynatremia and dyskalmia and associated factors among adult patients admitted to ICUs at Black lion specialized hospital, St peter's and Yekatit 12 hospital. Prepared by investigator after reviewing literatures.

After taking written informed consent and ethical approval, the following data will be retrieved by reviewing patient's charts and interviewing patients.

Eligibility criteria

Inclusion Criteria	
- Is the patient greater than 18?	Yes□ No□
- Has the patient stayed for > 24hrs in the ICU?	Yes□ No□
- At least 2 electrolyte determinations at least 24 hrs. apart during ICU stay?	Yes□ No□
Exclusion Criteria	
- Patient has been previously admitted to ICU and analyzed?	Yes□ No□

Sociodemographic factors

No	Variables	Response
101	Card number	
102	Age	
103	Sex	Male□ Female□
104	Marital status	Married□ Single□ Divorced□ Widowed □
105	Living area	Urban□ Rural□ Semi urban□
106	Region	Addis Ababa□ Oromia□ Amhara□ SNNRP□ Others: ____

B. Admission diagnosis

C. lab parameters

No	Lab parameters	Date of admission											
301	Sodium (Meq/l)												
302	Potassium (Meq/l)												
303	Magnesium (Meq/l)												
304	Calcium (mg/dl)												
305	Chloride (Meq/l)												
306	Creatinine (Mg/dl)												
307	Urea (mg/dl)												
308	AST (IU/l)												
309	ALT (IU/l)												
310	ALP (IU/l)												

D. Has the patient taken these drugs?

No	Medications		Yes	No
401	Diuretics	Frusemide		
		Thiazide		
		Spironolactone		
402	Vasoactive	Epinephrine		
		Norepinephrine		
		Dopamine		
403	Beta blocker			
404	ACEI/ARBs			
405	Antibiotics			
406	Corticosteroids			
407	Sedatives			
408	Proton pump inhibitors			
409	Antiplatelets and anticoagulants	Aspirin		
		Heparin		
		Warfarin		
		NOACs		
410	IV fluids	Normal saline		
		D5W		
		Ringer's lactate		

E. Clinical parameters

5.1 Diagnosis of AKI during Stay

A. Yes

B. No

5.2 Has the patient undergone Renal replacement therapy.

A. Yes

B. No

5.3 Blood product Transfusion

A. Yes

B. No

5.4 Is the patient diabetic?

A. Yes

B. No

5.5 What is the calculated qSOFA score.

F. Outcome

5.1 Discharged

A. Improved

I. How long the patient stayed?.....

B. Went Against medical advice.

C. Transferred to another facility.

5.2 Died

2. Information Sheet

Title of Project: The magnitude of dysnatremia and dyskalmia and associated factors among adult patients admitted to ICUs at Black lion specialized hospital, St peter's and Yekatit 12 hospital.

Name of the Investigators: Atikelt Zerihun, Addisu Melkie

My name is Dr._____, and I am working with the renal disease team. You are invited to participate in this study. Before you decide to take part, it is important for you to understand why this research is being done and what it involves. Please take time to read/listen to the following information carefully. Raise question if there is anything not clear. Thank you for the time you have spent already.

Background to the study.

We would like to see the prevalence of the burden of dysnatremia and dyskalemia and the associated factors in critical care settings. Electrolyte imbalance is an important cause of morbidity and mortality in critically ill patients. You will be interviewed with a prepared questionnaire; your chart will be revised for clinical, laboratory findings.

Possible harms. There is no harm in participating in this study.

Benefits. The findings of the study may help plan for care of critically ill patients with early diagnosis and management of electrolyte imbalance.

Confidentiality. All information which is collected about you during the research will be strictly confidential.

Autonomy. All the information you give us is highly valuable to the study. It is up to you to decide whether to take part or not. If you decide to participate, you will be given this information sheet to keep and be asked to sign a consent form. Whether you consent or do not consent to be part of the study, your rights for care in the health care facility will not be compromised and you can withdraw from the study any time.

What will happen to the research? The data will be collected over four months period and the result will be available in 8 months' time, and we hope to disseminate the result publishing it on national and/or international journals.

Who is organizing and funding the research? Research is funded by Addis Ababa University. The research will be reviewed by the Institutional Review Board of College of health Sciences, Addis Ababa University.

Thank you in advance!

PI address: Atikelt Zerihun, MD

Internal Medicine Resident at Addis Ababa University

Mob. No.: 0912397071

e-mail: Atikeltzerihun@gmail.com

3. Informed Consent Form

Electrolyte imbalance is a common cause of morbidity and mortality in critically ill patients. These patients have increased morbidity and mortality which can be reduced by early detection and correction on the electrolyte abnormalities. This study aims to look for the burden of dynatremia and dyskalemia in critically ill patients. The information obtained will be used by policy makers and managing physicians for better care of individual patient and the strategic control of risk factors.

For this reason, we kindly request you to participate in the study by responding to the interview, allowing to review your medical record and to undergo some investigations. We assure you that confidentiality of the information obtained is kept. If you have any questions, we will be so happy to entertain them.

I confirm that I have understood what has been read/what I have read has been clear to me, and I have agreed to participate in the study.

Name_____

Signature_____ Date_____

4. Investigators Signature Form

I agree to conduct the study in accordance with the relevant, current protocol and will not make changes to the protocol without permission of Department of Internal Medicine, except when necessary, to protect the safety, rights, or welfare of study participants. I agree to personally conduct or supervise this study. I will ensure that the requirements relating to obtaining informed consent and Ethics Committee (EC) or Institutional Review Board (IRB) review and are met. I agree to maintain adequate and accurate study records and to make those records available for inspection by the department or unit heads, hospital administrators, and/or other applicable regulatory entities. I also agree to promptly report to the EC/IRB all changes to the study and all unanticipated problems involving risks to human subjects or others. I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments.

Principal Investigator: _____

Signature: _____ Date: _____